CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

ImmunityBio (IBRX) said on Thursday that its QUILT-2.005 clinical trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

Aidixi combined with BCG showed 100% clinical complete response rates at three and six months in high-risk NMIBC patients with HER2 expression. Event-free survival at six months was 100% for patients ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...